Compare Becton Dickinson and Co (BDX) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Becton Dickinson and Co trades at $156.26 (market cap $41.51B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $59.81. The key difference: Becton Dickinson and Co pays a 2.79% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | JEPQ | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $185.39 | $61.46 |
52-Week Low | $135.49 | $53.77 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
JEPQ trades at $59.59, down 1.52% on the day, with a neutral technical signal overall. The fund provides Nasdaq-100 exposure with a covered-call strategy aimed at generating monthly income, highlighted by recent dividend payments. News coverage focuses on its high distribution yield and role in retirement portfolios, though some articles question its long-term performance versus the underlying index.
The outlook balances high income potential against capped upside in strong bull markets. Key risks include underperformance during tech rallies and dependence on options income. Analyst sentiment is mixed, weighing yield attractiveness against total return trade-offs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
